TG Therapeutics (NASDAQ:TGTX) Given Buy Rating at HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $45.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 226.56% from the stock’s previous close.

TGTX has been the subject of several other reports. StockNews.com cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. B. Riley lifted their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $29.00.

TG Therapeutics Stock Down 1.5 %

Shares of TGTX stock opened at $13.78 on Thursday. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 689.34 and a beta of 2.30. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67. The company’s fifty day moving average price is $15.11 and its 200-day moving average price is $13.91. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The firm had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same period last year, the firm earned ($0.39) EPS. Sell-side analysts expect that TG Therapeutics will post -0.12 EPS for the current fiscal year.

Insider Activity

In other news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Pingora Partners LLC bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $27,000. Coppell Advisory Solutions LLC bought a new position in TG Therapeutics in the second quarter worth approximately $46,000. Providence Capital Advisors LLC grew its stake in TG Therapeutics by 1,403.9% in the first quarter. Providence Capital Advisors LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,783 shares in the last quarter. KBC Group NV bought a new position in TG Therapeutics in the fourth quarter worth approximately $54,000. Finally, PNC Financial Services Group Inc. grew its stake in TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.